Carroll Investors’s Thermo Fisher Scientific TMO Stock Holding History

Carroll Investors’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-485	Closed	-$244K	–	31
2023 Q3	$244K	Buy	+485	New	+$258K	0.22%	25
2023 Q2	–	Sell	-485	Closed	-$280K	–	35
2023 Q1	$280K	Hold	485	–	–	0.23%	36
2022 Q4	$270K	Hold	485	–	–	0.29%	35
2022 Q3	$250K	Buy	+485	New	+$271K	0.2%	35

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Carroll Investors's TMO Position: Q4 2023 in Review

Carroll Investors sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 485 shares — an estimated $244K sold.

Carroll Investors first reported a position in TMO in Q3 2022 and held it in 4 quarters. The position peaked at $280K in Q1 2023. 2,491 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

Carroll Investors reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
Carroll Investors sold 485 Thermo Fisher Scientific shares in Q4 2023, an estimated $244K.
Carroll Investors first reported a position in Thermo Fisher Scientific in Q3 2022 and held it in 4 quarters.
Carroll Investors's Thermo Fisher Scientific position peaked at $280K in Q1 2023.
2,491 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Carroll Investors's 13F filing for Q4 2023, filed 14 Feb 2024.